Kimberly Chew is senior counsel in Husch Blackwell LLP’s virtual office, The Link, where she co-leads the firm’s psychedelic and emerging therapies practice. With a robust background in biotech research, Kimberly guides life sciences clients through the intricate landscape of clinical trials, FDA regulations, and academic research compliance. Her practice encompasses regulatory due diligence and intellectual property enforcement, particularly in patent infringement and validity. She helps drug developers and entrepreneurs navigate the complexities of the life sciences sector, addressing regulatory and commercial challenges to achieve business goals.

Eric C. Ulchaker brings over a decade of entrepreneurial experience, including more than two years in venture capital, with a proven track record of successful ventures. He previously served as Fund Manager for the Pit Road Fund, a $23 million pre-seed and seed-stage venture fund affiliated with the University of Notre Dame, and played a key role in raising the 1842 Fund – a partnership between High Alpha Innovation and the University of Notre Dame – where he led diligence efforts following the fund’s initial $17.5 million close. Eric is currently a Managing Partner at Serial Stage Venture Partners (SSVP), a Cleveland-based, healthcare-focused investor network with over 150 members. He is also an active angel investor. Passionate about MedTech, BioTech, and HealthTech, Eric has supported startups such as Pulmonary Apps, Apportis, and Million Marker, a Y Combinator-backed company.

‍

As the Executive Director of the Institute for the Global Entrepreneur (IGE), UC San Diego, Dennis has merged entrepreneurship training with an intensive acceleration environment to deliver a blend of education, mentorship, and resources to scale deep-tech startups. Since its establishment in 2016, IGE has sponsored both regional and international startups in healthcare and life sciences seeking to commercialize their research. As a founder in several startups, Dennis has built a career with a balance of business and technology expertise, holding executive positions in R&D, operations, sales and business development.

Ms. Pelletier is an expert in women’s health, with insight driven by both intensive consumer research and deep commercial experience in the global markets with products addressing women’s health spanning every stage in their reproductive journey, from puberty to menopause. Her career in the pharmaceutical industry has spanned more than three decades, during which she has launched pharmaceutical brands worldwide and expanded indications for female healthcare brands in multiple countries. She is a published author, TEDx and keynote speaker, executive coach and staunch advocate for innovation in women’s healthcare. During her 10-year tenure as Chief Executive Officer, President and Executive Director of Evofem Biosciences, Inc. (OTCPK: EVFM), Ms. Pelletier has led the company through its transition to the public market, the approval of PHEXXI, the first and only hormone-free, on-demand prescription contraceptive vaginal gel, the acquisition of SOLOSEC, an FDA-approved single-dose oral antimicrobial agent for the treatment of two common sexual health infections: trichomoniasis and bacterial vaginosis, and four consecutive years of net sales growth.

Amy Jung is an investor with experience in emerging technology, healthcare, and early-stage venture capital. Before joining Llama Ventures, she worked at Redesign Health, driving innovation and portfolio growth across health and life sciences startups, and is an active member of All Raise and Global Women in VC. Amy holds a B.S. in Molecular Biology and an M.S. in Data Science and Machine Learning from the University of California, Berkeley.

Brian brings over 25 years of biopharmaceutical development experience and a deep understanding of the challenges and opportunities in advancing innovative therapies from research through commercialization. At Peregrine Bio, Brian partners with leading industry stakeholders to navigate complex trends in biomanufacturing, supporting clients as they transition through development and toward a final commercial vision. He has hands-on expertise in CMC and operational strategy, scalable manufacturing platforms, process validation, and CMC regulatory strategy across the bioproduction value chain.

Paola Torre is a Venture Partner at Aquillius Ventures and Board Member at Life Science Angels, where she focuses on sourcing and evaluating early-stage biotech and therapeutic companies. With a background spanning both venture investing and biopharma R&D at BioMarin Pharmaceutical, Paola brings a cross-disciplinary perspective at the intersection of science, strategy, and innovation. She is passionate about advancing women’s leadership in life sciences and supporting founders developing transformative health technologies.

Sabrina Runbeck, MPH, MHS, PA-C is a Fractional COO/CSO, co-founder of PulsePoint Path, Venture Partner at MedStartr Capital, and Chief Strategist of Health Board Advisors. She predicts healthcare company sustainability and scalability through human, social, and intellectual capital assessments. A 3x international bestselling author, TEDx speaker, and top 5% podcast host, she champions women clinicians transitioning to leadership and investment roles.

With over 12 years of experience spanning global regulatory affairs, drug development, and clinical research, Odette brings a wealth of expertise—particularly in advancing innovative therapies for rare and underserved diseases. Her career has been shaped by a deep commitment to ensuring that novel treatments are both effective and safe, especially for vulnerable populations including children.

Reetu Gupta is Chair of the Health Scientific Board at the Maroon Research Institute, where she leads initiatives at the intersection of women’s health, healthy longevity, and climate-driven determinants of health. She also serves as the Head of California & India Partnerships & Community for the Institute. Reetu is a seasoned strategic leader reflecting a 20+ year track record in healthcare, finance, and is passionate about how Climate has a direct impact on Health. Previously Vice President Customer Success at Brightline Health and 10+ year tenure at Kaiser Permanente, encompassing new program development, strategic partnerships and M&A.  She brings her healthcare and innovation experience advising purpose-driven founders.

Christa has practiced public accounting since 2013 and is a member of the firm’s Technology, Communications & Media, and Life Sciences Practice. She primarily works with biotechnology, pharmaceutical drug discovery, medical devices, and laboratory testing companies. Christa provides tax consulting and compliance services such as tax return preparation and ASC 740 calculations for her start up through public clients, as well as being a connector of people to the vast resources available for scaling business in the life sciences space at Baker Tilly, including software automation, cybersecurity, clinical trial risk management & consulting, audit/IPO readiness and commercial compliance. Christa values the importance of being an advisor from incorporation through the client’s preferred exit and works with her clients to provide guidance to meet the needs at every step of the business life cycle.

She have successfully founded and scaled institutional firms and ventures; establishing a track record globally over 20+ years as a transformative leader, astute institutional investor; arranger (US$30bn+); and catalytic entrepreneur across private credit and growth equity (as both GP & Limited Partner)Managing Partner for Maroon Venture Fund I LP investing anchor capital to advance Health span & Longevity Science by closing material innovation & funding gaps in proactive, personalized Preventative Health for chronic Population Health conditions and direct Climate impact on Health. Coming from an innovative, very successful, multi-generational family business in Precision Medicine, Genetics & Preventative Health, I have an intrinsic respect & commitment to addressing single digit statistics undermining early detection, diagnosis & prevention of chronic Pop. Health conditions

A seasoned investment professional who has successfully identified and invested in hundreds of companies with a focus on the Biotech/MedTech sector.

Dr. Eisner brings a wealth of expertise and a deep commitment to advancing women’s health. Her background includes extensive leadership in clinical development, regulatory affairs (former FDA drug regulator for biologics and devices), pharmacovigilance, and international science policy. She is a Venture Partner, a pharmacovigilance expert, and has served on the boards of both a large healthcare company and a tech start-up. In addition, Dr. Eisner is a bioethicist and an engaging speaker, with significant experience in research, development, and all phases of clinical trials. She graduated from University of California, San Diego Medical School, completed an internship at University of California, San Francisco, and completed her residency at the University of Washington in Seattle. Dr. Eisner currently resides in the Boston area, and her areas of therapeutic expertise include rare diseases, immunology, pain and addiction medicine, sepsis, infectious diseases, oncology, and coagulation disorders.

Reza Kazemipour is the CEO and Founder of SixthRing, a performance and health optimization company leveraging diagnostics, biometrics, and AI to help individuals and organizations operate at their highest level. With over 30 years of global leadership experience across startups, venture capital, and corporate strategy, Reza brings a unique blend of execution, vision, and operational rigor to the human performance space. His background in the U.S. Navy instilled a lifelong discipline and drive, which he now channels into building scalable platforms that improve physical, cognitive, and emotional resilience, especially in high-stakes environments like healthcare, elite performance, and executive leadership.

‍

Ray Jordan is an investment manager at Elmstead Partners LLC and the Managing Director of Putnam Insights LLC, a communications and strategic advisory firm majority-owned by Elmstead. Elmstead Partners is a multi-generational family trust focused on transformational early-stage life sciences and technology infrastructure investments, with a portfolio of more than 50 private life sciences companies. In parallel, Rayleads Putnam Insights, where he works with founders, executives, and investors to support corporate strategy, positioning, capital formation, and stakeholder engagement from early development through growth and strategic collaboration.